BR112022002253A2 - Método para preparar ivosidenibe e um intermediário do mesmo - Google Patents

Método para preparar ivosidenibe e um intermediário do mesmo

Info

Publication number
BR112022002253A2
BR112022002253A2 BR112022002253A BR112022002253A BR112022002253A2 BR 112022002253 A2 BR112022002253 A2 BR 112022002253A2 BR 112022002253 A BR112022002253 A BR 112022002253A BR 112022002253 A BR112022002253 A BR 112022002253A BR 112022002253 A2 BR112022002253 A2 BR 112022002253A2
Authority
BR
Brazil
Prior art keywords
ivosidenib
preparing
synthesize
present application
application relates
Prior art date
Application number
BR112022002253A
Other languages
English (en)
Inventor
Paul Sizemore Jacob
Zhang Shijie
Huu Vo Nha
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of BR112022002253A2 publication Critical patent/BR112022002253A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

MÉTODO PARA PREPARAR IVOSIDENIBE E UM INTERMEDIÁRIO DO MESMO. O presente pedido refere-se a um método para preparar um solvato de etanol cristalino substancialmente puro diastereomericamente do Composto IIa e seu uso para sintetizar Ivosidenibe.
BR112022002253A 2019-08-08 2020-08-07 Método para preparar ivosidenibe e um intermediário do mesmo BR112022002253A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962884480P 2019-08-08 2019-08-08
PCT/US2020/045368 WO2021026436A1 (en) 2019-08-08 2020-08-07 A method for preparing ivosidenib and an intermediate thereof

Publications (1)

Publication Number Publication Date
BR112022002253A2 true BR112022002253A2 (pt) 2022-07-05

Family

ID=74504162

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022002253A BR112022002253A2 (pt) 2019-08-08 2020-08-07 Método para preparar ivosidenibe e um intermediário do mesmo

Country Status (29)

Country Link
US (1) US20230025411A1 (pt)
EP (1) EP4010331B1 (pt)
JP (1) JP2022544143A (pt)
KR (1) KR20220061971A (pt)
CN (1) CN114555584A (pt)
AU (1) AU2020327013A1 (pt)
BR (1) BR112022002253A2 (pt)
CA (1) CA3150028A1 (pt)
CL (1) CL2022000310A1 (pt)
CO (1) CO2022001991A2 (pt)
CR (1) CR20220090A (pt)
DK (1) DK4010331T3 (pt)
EC (1) ECSP22016924A (pt)
ES (1) ES2967909T3 (pt)
FI (1) FI4010331T3 (pt)
HR (1) HRP20231618T1 (pt)
HU (1) HUE064193T2 (pt)
IL (1) IL290377A (pt)
LT (1) LT4010331T (pt)
MA (1) MA56783B1 (pt)
MD (1) MD4010331T2 (pt)
MX (1) MX2022001619A (pt)
PE (1) PE20221761A1 (pt)
PL (1) PL4010331T3 (pt)
PT (1) PT4010331T (pt)
RS (1) RS64934B1 (pt)
SI (1) SI4010331T1 (pt)
TW (1) TW202120491A (pt)
WO (1) WO2021026436A1 (pt)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006067445A2 (en) 2004-12-22 2006-06-29 Astrazeneca Ab Csf-1r kinase inhibitors
ATE541844T1 (de) 2005-12-21 2012-02-15 Abbott Lab Antivirale verbindungen
US9474779B2 (en) * 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
NZ723859A (en) 2014-03-14 2023-01-27 Servier Lab Pharmaceutical compositions of therapeutically active compounds and their uses
WO2019104318A1 (en) * 2017-11-27 2019-05-31 Teva Pharmaceuticals Usa, Inc. Solid state forms of ivosidenib
CA3103498A1 (en) * 2018-07-06 2020-01-09 Agios Pharmaceuticals, Inc. Ivosidenib forms and pharmaceutical compositions
WO2020127887A1 (en) * 2018-12-21 2020-06-25 Sandoz Ag Process for the preparation of an intermediate product of ivosidenib

Also Published As

Publication number Publication date
MA56783B1 (fr) 2023-10-31
RS64934B1 (sr) 2023-12-29
WO2021026436A1 (en) 2021-02-11
CA3150028A1 (en) 2021-02-11
CL2022000310A1 (es) 2022-11-25
TW202120491A (zh) 2021-06-01
PL4010331T3 (pl) 2024-03-11
MD4010331T2 (ro) 2024-03-31
AU2020327013A1 (en) 2022-03-24
EP4010331B1 (en) 2023-10-04
IL290377A (en) 2022-04-01
LT4010331T (lt) 2023-11-10
ECSP22016924A (es) 2022-06-30
SI4010331T1 (sl) 2024-02-29
ES2967909T3 (es) 2024-05-06
CR20220090A (es) 2022-08-24
JP2022544143A (ja) 2022-10-17
EP4010331A1 (en) 2022-06-15
KR20220061971A (ko) 2022-05-13
PE20221761A1 (es) 2022-11-11
CO2022001991A2 (es) 2022-07-29
PT4010331T (pt) 2024-01-08
DK4010331T3 (da) 2023-12-18
HUE064193T2 (hu) 2024-02-28
HRP20231618T1 (hr) 2024-03-15
FI4010331T3 (fi) 2023-12-28
US20230025411A1 (en) 2023-01-26
MX2022001619A (es) 2022-07-19
CN114555584A (zh) 2022-05-27

Similar Documents

Publication Publication Date Title
CL2022001392A1 (es) Compuestos tricíclicos sustituidos
WO2020047004A3 (en) Methods of generating an array
ECSP19020141A (es) Un esteroide 19-nor-c21-n-pirazolilo c3,3-disustituido cristalino
ECSP22057865A (es) Inhibidores de formas mutantes de egfr
CO2021015698A2 (es) Moduladores de thr-β y métodos de uso de estos
MX2021012756A (es) Derivado de un anillo inhibidor de btk, metodo de preparacion de este y aplicacion farmaceutica para este.
MX2021010314A (es) Derivados de tiazol como inhibidores de la secreción de proteínas.
UY38057A (es) Inhibidores de sarcómero cardíaco
PE20201464A1 (es) Conjugados anticuerpo anti-cd40-farmaco
EA202091979A1 (ru) Кристаллические формы и способы получения кристаллических форм соединения
WO2019023216A8 (en) INHIBITORS OF ROR GAMMA
BR112022009209A2 (pt) Derivado de amida e método de preparação e uso do mesmo na medicina
BR112022012512A2 (pt) Método para a preparação de l-glufosinato
CL2020002598A1 (es) Método para la preparación de una 1,2,4-triazolona 2,4,5-trisustituida
CL2022001456A1 (es) Tiofenocarboxamidas sustituidas y sus derivados
CL2022000892A1 (es) Derivados de 2–azaespiro[3.4]octano como agonistas de m4
CL2022000893A1 (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
BR112022002253A2 (pt) Método para preparar ivosidenibe e um intermediário do mesmo
CL2021001511A1 (es) Novedosa psicosa-6-fosfato fosfatasa, composición para la producción de psicosa que comprende la misma y procedimiento para la producción de psicosa mediante el uso de la misma
BR112022008647A2 (pt) Composto de imidazolidinona, método de preparação do mesmo e uso do mesmo
CL2019002967A1 (es) Proceso para la preparación de piperazina para la síntesis de derivados de pirazinocarbazol.
AR114477A1 (es) Método para la preparación de una 1,2,4-triazolona 2,4,5-trisustituida
AR107199A1 (es) Una forma cristalina de diclosulam, un proceso para su preparación y uso de este
AR125978A2 (es) Compuestos, composiciones y métodos
TR201910633A1 (tr) Si̇taglipti̇n i̇çeren efervesan tablet kompozi̇syonu